Central Nervous System Efficacy of Capmatinib in NSCLC With Brain Metastases With cfDNA Positive MET Alterations

NCT05567055 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Slow enrollment

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG: Capmatinib

Sponsor

Timothy Burns, MD, PHD

Collaborators

[object Object]